• Ta-Chuan Yu, Shan-Chi Yu, Ren-Ching Wang, Shih-Fan Lai, Chieh-Lin Jerry Teng, Jing-Wei Lin, Wan-Ling Lin, and Tai-Chung Huang.
• Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan.
• J Formos Med Assoc. 2022 Jul 1; 121 (7): 1215-1222.

Background/PurposeThe early progression of disease (POD) of Hodgkin lymphoma (HL) leads to a poor prognosis. To identify risk factors for early POD, this retrospective two-center cohort analysis was conducted.MethodsMedical records of HL patients between 1998 and 2020 from two referral centers were reviewed.ResultsTwo-hundred and sixty-nine patients were analyzed. The distribution of early vs. advanced stages was 51.1 vs. 48.9%, respectively. The 5-year progression free survival (PFS) was 63%, and the overall survival (OS) was 87% with a median follow-up of 52.0 months. The complete remission (CR) rate was 85.7%. Disease progression or relapsed disease occurred in 33.9% (n = 85) of patients while 17.0% of this cohort had early POD within 12 months of induction therapy. Patients with early POD had a worse median OS than those without (p < 0.001). Failure to achieve post-induction CR and high international prognostic score (IPS, 3-7) were independent risk factors for early POD. Compared with chemotherapy alone, consolidative radiotherapy after induction chemotherapy was associated with a lower risk of early POD (21.3% vs. 6.2%, p = 0.006).ConclusionHigh IPS was an independent risk factor for early POD, which was less observed in those with consolidative radiotherapy.Copyright © 2022 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

12 keywords...

hide…